Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?
Crossref DOI link: https://doi.org/10.1007/s12032-014-0476-8
Published Online: 2015-01-09
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sedef, Ali Murat
Köse, Fatih
Sümbül, Ahmet Taner
Doğan, Özlem
Beşen, Ali Ayberk
Tatlı, Ali Murat
Mertsoylu, Hüseyin
Sezer, Ahmet
Muallaoğlu, Sadık
Özyılkan, Özgür
Abalı, Hüseyin
Text and Data Mining valid from 2015-01-09